Parkinson's disease (PD) remains a major challenge in neurodegenerative drug development, particularly for disease-modifying therapies and regenerative approaches such as stem cell transplantation. In 2025, an expert panel from the Chinese Research Hospital Association released updated guidance on selecting preclinical PD models for drug and cell therapy evaluation.

This article summarizes key insights from the guideline-highlighting the distinctions among classical neurotoxin models, the strengths of genetic models, and the translational value of nonhuman primates (NHPs). As a CRO specializing exclusively in NHP pharmacology studies, Prisys Biotech provides validated PD models and quantitative evaluation platforms for mid- to late-stage translational research.

Neurotoxin-induced models remain widely used due to their accessibility, cost-effectiveness, and robust dopaminergic neuron loss. However, each model serves different experimental purposes.

MPTP Model (Mouse / Monkey)

Mechanism: MPTP is metabolized to MPP⁺, which selectively inhibits mitochondrial complex I, causing dopaminergic neuronal death.

Applications: Motor deficits and oxidative stress research

Pharmacological screening

PK/PD correlation studies

Model Variants:

Acute: Single high-dose injection with rapid symptoms but partial spontaneous recovery

Chronic: Repeated low-dose administration, mimicking progressive degeneration

Limitations:

Limited Lewy body formation

Mouse model shows strong recovery capacity

Mechanism:
Unilateral injection of 6-OHDA induces selective dopaminergic neuron degeneration. Motor asymmetry is quantified using apomorphine-induced rotations.

Applications:

Stem cell transplantation efficacy

Deep brain stimulation (DBS) studies

Advantages:

Clear, quantifiable rotation behavior

Straightforward surgical approach

Limitations:

Lack of α-synuclein aggregation

Does not capture chronic progressive pathology

Although widely used, these toxin models provide only partial recapitulation of human PD and are insufficient for evaluating long-term cell integration and safety-areas where NHPs are essential.

When investigating PD etiology or specific pathogenic pathways, genetic models enable controlled manipulation.

α-Synuclein (SNCA) Overexpression Models

Features:
Overexpression of human α-synuclein (e.g., A53T mutant) leads to protein aggregation and Lewy body–like pathology.

Applications:

• Familial PD mechanisms
• α-synuclein targeting therapeutics
• Cell therapy rescue studies

Parkin / DJ-1 Knockout Models

Features:
Models display mitochondrial autophagy defects and relatively mild dopaminergic loss but exhibit non-motor symptoms such as cognitive impairment.

Applications:

• Oxidative stress and mitochondrial dysfunction
• Early-stage disease mechanism research
• Although genetic models clarify molecular mechanisms, their clinical translatability remains limited. For cell therapy and advanced biologics, NHP models provide superior predictive value.

NHPs-particularly cynomolgus and rhesus monkeys-are the closest species to humans in terms of basal ganglia anatomy, neural circuitry, and behavioral phenotypes. They are recognized globally as the gold standard for evaluating cell therapies, viral gene therapies, and biologics targeting the CNS.

Modeling Approach

The guideline recommends chronic MPTP induction to mimic progressive dopaminergic degeneration and long-term functional decline.

Evaluation Framework

Comprehensive evaluation is essential for clinical translatability:

• Kurlan Rating Scale: Quantifies tremor, bradykinesia, posture, and gait
• Fine Motor Tasks: e.g., box-and-board or food retrieval tests assessing upper-limb dexterity
• Cognitive Function: Delayed-response tasks reflecting executive function impairment
• Imaging Support (optional): PET/SPECT/MRI for dopamine transporter visualization, cell survival tracking, and structural analysis

At Prisys Biotech, these behavioral and imaging readouts are integrated with our AI-based NHP Behavior Analysis System, enabling objective and high-resolution motor and cognitive quantification.

The guideline emphasizes multi-modal behavioral testing to ensure robust phenotyping:

These quantitative endpoints are essential for evaluating functional recovery following stem cell transplantation, gene therapy, or neuromodulatory interventions.

The 2025 guideline provides a structured decision-making framework:

• Drug Discovery (Screening & Optimization)

• Preferred: MPTP mouse or 6-OHDA rat
• Goal: Rapid efficacy screening and PK/PD correlation

Cell Therapy / Regenerative Medicine

Preferred: Chronic MPTP monkey model

Rationale: Long-term survival, integration, and safety assessment

Mechanism Studies

Genetic mechanisms: SNCA overexpression

Mitochondrial dysfunction: Rotenone model

Complex interactions: Combined genetic + neurotoxin approaches (e.g., α-synuclein overexpression + MPTP)

For studies intended for IND-enabling validation or late-stage translational research, NHPs offer unparalleled predictive value.

While animal models remain indispensable, emerging technologies are reshaping PD research:

iPSC-Derived Dopaminergic Neurons

Allow personalized drug testing using patient-specific cells.

Brain Organoid–Animal Chimeric Models

Enable in vivo evaluation of human-derived neuronal circuits and graft-host integration.

Integrated Approaches

Future PD modeling will likely combine:

• Classical NHP models
• Human-origin organoids
• Advanced imaging
• AI-driven quantitative behavioral analysis

to construct more accurate and clinically predictive disease systems.

About Prisys Biotech

Prisys Biotech specializes exclusively in NHP preclinical pharmacology, offering validated MPTP-induced PD monkey models and AAV-α-Synuclein Overexpression NHP Model, real-time imaging platforms, and AI-based behavioral quantification systems. We support global biotech and pharmaceutical partners in cell therapy evaluation, biologics development, and CNS translational research.